arrow
C

Chengzhi Zhou

广州呼吸健康研究院
H指数:42
被引数:6,115

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

甲磺酸厄洛替尼与吉非替尼作为EGFR突变非小细胞肺癌的一线治疗:一项随机、双盲、多中心III期研究

2026-08-130
OA
Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial

安罗替尼联合派安普利在二线治疗小细胞肺癌中的疗效及生物标志物探索:ALTER-L041期2临床试验结果

2026-07-220
OAAI
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)

奥希替尼联合或不联合萨沃利替尼治疗MET异常、EGFR突变非小细胞肺癌的一线治疗:随机II期试验(FLOWERS)

2026-01-130
OAAI
A public data-based molecular classification of small cell lung cancer by neuroactive signaling networks unveils distinct microenvironment landscapes and immunotherapy-related prognostic biomarkers

基于神经活性信号网络的小细胞肺癌公共数据分子分类揭示了独特的微环境景观和免疫治疗相关的预后生物标志物

2025-11-300
PRE
First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China

一线卡瑞利珠单抗联合培美曲塞和卡铂治疗伴脑转移的晚期非鳞非小细胞肺癌(CAP-BRAIN):一项在中国进行的多中心、开放标签、单臂、II期试验的最终结果

2025-11-120
OAAI
Sintilimab plus chemotherapy for first-line treatment of advanced pulmonary lymphoepithelioma-like carcinoma: Phase 2 trial

信迪利单抗联合化疗用于晚期肺淋巴上皮样癌的一线治疗:2期临床试验

2025-10-060
OAAI
International guidelines on the diagnosis and treatment of NUT carcinoma

NUT癌的诊断与治疗国际指南

2025-07-310
OAAI
Ginsenoside Rg1 exerts anti-arrhythmic effect by inhibiting ICaL through cAMP-PKA and PI3K-AKT signaling pathways in rat ventricular myocytes after myocardial ischemia-reperfusion injury

人参皂苷Rg1通过抑制心肌缺血再灌注损伤后大鼠心室肌细胞的ICaL,经由cAMP-PKA和PI3K-AKT信号通路发挥抗心律失常作用。

2025-05-230
OA